New diabetes drug aims to slow kidney failure in High-Risk patients
NCT ID NCT07116928
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding ganagliflozin tablets to standard care can slow kidney disease progression in 1,244 adults with type 2 diabetes and chronic kidney disease. Participants will take either ganagliflozin or a placebo daily for 120 weeks. The main goal is to measure changes in kidney function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ganagliflozin
What this could lead to
If it works, this could provide a new treatment option to help preserve kidney function and delay the need for dialysis or transplant in people with type 2 diabetes and chronic kidney disease.
What could go wrong
This is a phase 4 trial, so the drug is already approved, but it may not show significant benefit over placebo. Side effects could include dehydration, urinary tract infections, or other risks common to this class of drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••